Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention: Journal of the American College of Cardiology

M. Lamberts, G. H. Gislason, J. B. Olesen, S. L. Kristensen, A. M. S. Olsen, A. Mikkelsen, C. B. Christensen, G. Y. H. Lip, L. Kober, C. Torp-Pedersen, M. L. Hansen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Objectives The purpose of this study was to investigate the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimens in atrial fibrillation (AF) patients after myocardial infarction (MI) or percutaneous coronary intervention (PCI). Background The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications. Methods A total of 12,165 AF patients hospitalized with MI and/or undergoing PCI between 2001 and 2009 were identified by nationwide registries (60.7% male; mean age 75.6 years). Risk of MI/coronary death, ischemic stroke, and bleeding according to antithrombotic treatment regimen was estimated by Cox regression models. Results Within 1 year, MI or coronary death, ischemic stroke, and bleeding events occurred in 2,255 patients (18.5%), 680 (5.6%), and 769 (6.3%), respectively. Relative to triple therapy (oral anticoagulation [OAC] plus aspirin plus clopidogrel), no increased risk of recurrent coronary events was seen for OAC plus clopidogrel (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.48 to 1.00), OAC plus aspirin (HR: 0.96, 95% CI: 0.77 to 1.19), or aspirin plus clopidogrel (HR: 1.17, 95% CI: 0.96 to 1.42), but aspirin plus clopidogrel was associated with a higher risk of ischemic stroke (HR: 1.50, 95% CI: 1.03 to 2.20). Also, OAC plus aspirin and aspirin plus clopidogrel were associated with a significant increased risk of all-cause death (HR: 1.52, 95% CI: 1.17 to 1.99 and HR: 1.60, 95% CI: 1.25 to 2.05, respectively). When compared to triple therapy, bleeding risk was nonsignificantly lower for OAC plus clopidogrel (HR: 0.78, 95% CI: 0.55 to 1.12) and significantly lower for OAC plus aspirin and aspirin plus clopidogrel. Conclusions In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.

Original languageEnglish
JournalJournal of the American College of Cardiology
Volume62
Issue number11
Pages (from-to)981-989
Number of pages9
ISSN0735-1097
DOIs
Publication statusPublished - 10. Sep 2013

Keywords

  • antithrombotic treatment atrial fibrillation bleeding myocardial infarction stroke NORTH-AMERICAN PERSPECTIVE LONG-TERM ANTICOAGULATION RE-LY TRIAL ANTITHROMBOTIC THERAPY CONSENSUS DOCUMENT TRIPLE THERAPY NATIONWIDE COHORT EUROPEAN-SOCIETY SYNDROME AND/OR WORKING GROUP

Fingerprint Dive into the research topics of 'Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention: Journal of the American College of Cardiology'. Together they form a unique fingerprint.

Cite this